What are the advantages and disadvantages of performing both chorionic villus sampling (CVS) and amniocentesis for invasive prenatal diagnostic testing in pregnancy?

You Should NOT Perform Both CVS and Amniocentesis on the Same Pregnancy

Performing both chorionic villus sampling and amniocentesis in the same pregnancy is not recommended and represents unnecessary dual exposure to procedural risks without clinical benefit. These are alternative diagnostic procedures—you choose one based on timing, clinical indication, and patient preference, not both 1.

Why This Approach Makes No Sense

Redundant Testing Without Added Value

• Both procedures provide the same diagnostic information—definitive karyotyping for aneuploidy and genetic conditions 1
• Once you have a diagnostic result from either procedure, repeating the test with a different method adds no clinical value
• You're essentially asking the same question twice using different sampling techniques

Compounding Procedural Risks

Each invasive procedure carries independent risks that would be additive:

CVS risks (per procedure):

• Pregnancy loss risk: approximately 0.2-0.3% above baseline 1
• Technical failure requiring repeat: 1-2% 2
• Confined placental mosaicism requiring follow-up amniocentesis: 1-2% 2

Amniocentesis risks (per procedure):

• Pregnancy loss risk: approximately 0.1-0.3% above baseline 1, 2
• Technical failure: lower than CVS 2

Performing both would double the exposure to:

• Miscarriage risk
• Infection risk
• Bleeding complications
• Maternal anxiety and discomfort
• Need for anti-D prophylaxis (if Rh-negative)

The Correct Clinical Algorithm: Choose ONE

Choose CVS (11+0 to 13+6 weeks) when:

• Earlier diagnosis is prioritized (first trimester results)
• Patient desires earlier decision-making regarding pregnancy management
• High-risk screening results available in first trimester
• Transabdominal approach is technically feasible 1

Choose Amniocentesis (≥15+0 weeks) when:

• CVS window has passed
• Neural tube defect evaluation is needed (AFP analysis)
• Lower technical failure rate is desired
• Slightly lower pregnancy loss rate is prioritized 2, 3

The Only Exception: Sequential Testing for Specific Indications

The only scenario where both procedures might occur in the same pregnancy is when CVS reveals confined placental mosaicism (chromosomal abnormality in placental tissue but not necessarily in fetus). In this specific situation:

• CVS is performed first at 11-13 weeks
• Results show mosaicism (occurs in 1-2% of cases) 2
• Follow-up amniocentesis at ≥15 weeks is then medically indicated to clarify true fetal karyotype
• This is sequential diagnostic clarification, not elective dual testing

Key Clinical Pitfalls to Avoid

Don't:

• Order both procedures "just to be sure"—this reflects misunderstanding of diagnostic testing principles
• Repeat testing because of parental anxiety without medical indication
• Use one procedure to "confirm" the other when results are concordant with ultrasound findings

Do:

• Provide individualized counseling about timing preferences (earlier CVS vs. later but slightly safer amniocentesis) 1
• Use your local institutional data on procedure-related complications when counseling 1
• Ensure the operator is appropriately trained in the chosen technique 1

Evidence Quality Note

The 2022 RCOG Green-top Guideline 1 provides the authoritative framework, supported by the 2017 Cochrane systematic review 2 showing that second trimester amniocentesis remains the safest single procedure (though CVS offers earlier diagnosis with only marginally higher risk). The evidence consistently shows these are alternative, not complementary procedures.